KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Jazz Pharmaceuticals (JAZZ) Accumulated Depreciation & Amortization (2016 - 2026)

Jazz Pharmaceuticals has reported Accumulated Depreciation & Amortization over the past 16 years, most recently at $41.6 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 26.83% year-over-year to $41.6 million; the TTM value through Dec 2025 reached $41.6 million, up 26.83%, while the annual FY2025 figure was $41.6 million, 26.83% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $41.6 million at Jazz Pharmaceuticals, down from $171.2 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $171.6 million in Q1 2025 and troughed at $26.7 million in Q4 2021.
  • A 5-year average of $99.4 million and a median of $97.3 million in 2022 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: soared 42.78% in 2021 and later grew 0.33% in 2023.
  • Year by year, Accumulated Depreciation & Amortization stood at $26.7 million in 2021, then grew by 13.48% to $30.3 million in 2022, then increased by 0.33% to $30.4 million in 2023, then increased by 7.89% to $32.8 million in 2024, then grew by 26.83% to $41.6 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for JAZZ at $41.6 million in Q4 2025, $171.2 million in Q3 2025, and $166.3 million in Q2 2025.